Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes will comply with the requirements of the protocol.~* Written informed consent obtained from the subject.~* A male or female aged 70 years or older at the time of the first vaccination.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy History of HZ.~* Previous vaccination against varicella or HZ.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Additionally, consider allergic reactions to other material or equipment related to study participation.~* Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.~* Receipt of immunoglobulins and/or any blood products within the 90 days preceding the first dose of study vaccine or planned administration during the study period.~* Administration or planned administration of any other immunizations within 30 days before the first or second study vaccination or scheduled within 30 days after study vaccination. However, licensed non-replicating vaccines may be administered up to 8 days prior to each dose and/or at least 14 days after any dose of study vaccine.~* Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.~* Acute disease and/or fever at the time of enrolment.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Zoster vaccine group (Type: EXPERIMENTAL): Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
- Placebo group (Type: PLACEBO_COMPARATOR): Subjects will receive NaCl solution placebo according to a 0, 2-month schedule

Based on this trial design, predict the completion outcome and termination type (if applicable).